EGF and neoplasm: SAP is a selective, potent, and competitive ATP inhibitor of EGFR and receptor tyrosine-protein kinase (erbB-2) that met its primary endpoint in phase 2/pre-phase 3 trials.1 SAP was found to be a more potent inhibitor of EGF-driven cellular proliferation in various tumor cell lines when compared to gefitinib, the previous first line clinical TKI.